Benjamin L. Adams

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Linda M. Rorick‐Kehn, Jeffrey M. Witkin, Michael A. Statnick et al. · Neuropharmacology · 2013 · 148 citations

Psychoactive Drug, Psychiatry, Functional Selectivity +7

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models

Rachel I. Anderson, Howard C. Becker, Benjamin L. Adams et al. · Frontiers in Neuroscience · 2014 · 96 citations · Full text

Substance Use, Orexin-2 Receptor Antagonists, Pharmacotherapy +19

The effect of “cap” analogs on reovirus mRNA binding to wheat germ ribosomes. Evidence for enhancement of ribosomal binding via a preferred cap conformation.

Benjamin L. Adams, Michael K. Morgan, S. Muthukrishnan et al. · Journal of Biological Chemistry · 1978 · 78 citations · Full text

A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models

Linda M. Rorick‐Kehn, Roberto Ciccocioppo, Conrad J. Wong et al. · Alcoholism Clinical and Experimental Research · 2016 · 60 citations · Full text

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

Kjell Svensson, Beverly A. Heinz, John M. Schaus et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 45 citations · Full text